On the stock market since 2020, it operates in the world of health and science. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Revenue is spread across several lines; no single product carries the company.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 62% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $4.7B a year; the problem isn’t sales — it’s costs running above that number.
Over the last 12 months, company executives reported 23 buys and 8 sells. Management buying with its own money is usually read as a good sign.
A loss of $232M against $4.7B in annual sales.
At the current pace of spending, the cash lasts about 2.3 years. After that, the company needs to find new money.
On our five-subject report card, ELAT sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: ELAT has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.